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Systemic sclerosis (SSc; scleroderma) is a sys-
temic autoimmune disease characterised by diverse 
skin and internal organ involvement. The underly-
ing pathology consists of fibrosis caused by fibro-
blast dysfunction and small vessel vasculopathy. It is 
much rarer in childhood, occurring only 1 in 1 mil-
lion children, and comprises approximately 3-10% 
of the adult incidence [1,2]. Only one tenth of ju-
venile scleroderma (jSSc) patients exhibit disease 
onset before 16 years of age, with patients under the 
age of 10 having an equal distribution of males and 
females. However, beyond this age, the predomi-
nance females in the adult patient population is in-
creasing [3]. The currently published data suggest 
a dominance of the diffuse subset in children [3]. 
Because jSSc is considered as an orphan disease, 
the diagnosis very often takes several months. [4,5]. 
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Pediatric patients have less pulmonary and  gastroesophageal 
involvement and the CREST-syndrome is not observed in the 
pediatric population [3]. Scleroderma may overlap with other 
autoimmune syndromes (e.g., poly/dermatomyositis, SLE), 
particularly in childhood [6]. Pediatric patients experience 
better survival rates compared to adults, as the 5-year survival 
rate was found to be approximately 93-95% [7,8]. The reasons 
for these improved outcomes are probably due to the lower 
frequency of comorbidities and less pulmonary and pulmo-
nary arterial involvement in children [7]. Treatment options in 
juvenile scleroderma are very similar, frequently adapted from 
the adult ’scleroderma world’, and are concerned with the de-
velopment of the child [1]. In the present paper, we attempt to 
review the hallmarks of this heterogenous disease, concentrat-
ing on novelties, new results and recommendations.
Diagnosis and Classification
In 1980, the American College of Rheumatology (ACR) 
submitted its diagnostic tool for systemic sclerosis [9]. The 
diagnosis is made if patients exhibit the major criterion of bi-
lateral skin thickening proximal to the MCP joints, or if not 
satisfied, meet at least two minor criteria (sclerodactily, typi-
cal fingertip lesions, pulmonary fibrosis). More recently, two 
subsets of scleroderma were introduced, including limited and 
diffuse cutaneous disaese [10]. Other subsets were proposed 
as well, such as early or limited disease and SSc sine scleroder-
ma (without skin symptoms) [11,12]. Several studies revealed 
that the 1980 ACR criteria can miss up to 20% of the patients 
with early and limited cutaneous SSc [13]. However, by that 
time new diagnostics tools, including the discovery of autoan-
tibodies, appeared [14].
The scleroderma working group of the Pediatric Rheu-
matology European Society developed a preliminary classifi-
cation criteria for juvenile systemic sclerosis [15]. The major 
criterion is the same skin thickening/induration as defined by 
the ACR. Minor criteria include peripheral vascular changes 
(Raynaud’s phenomenon, nailfold capillary abnormalities, 
digital tip ulcers), and gastrointestinal, cardial, renal, and res-
piratory changes, as well as the presence of autoantibodies 
(described later on). Neurologic symptoms (neuropathy and 
carpal tunnel syndrome) and musculoskeletal abnormalities 
(tendon friction rubs, myositis, arthritis) are also listed as mi-
nor criteria. A child exhibiting the major and at least two mi-
nor criteria can be classified as having jSSc [15]. 
The ACR and the European League Against Rheuma-
tism (EULAR) published their joint criteria for systemic scle-
rosis in 2013 [14], which is similar to the preliminary pediatric 
classification criteria, with the difference being that certain 
clinical presentations carry a greater weight in the diagnosis. 
It also affirms the diagnostic value of bilateral skin thickening 
mentioned above. In addition to the previous minor criteria, 
telangiectasias, abnormal capillaroscopy, pulmonary arterial 
hypertension (PAH), Raynaud’s phenomenon and SSc-relat-
ed antibodies are introduced. Common symptoms, such as 
calcinosis, flexion contractures of the fingers, friction rubs and 
dysphagia did not seem to improve sensitivity or specificity in 
adults, so they have failed to gain inclusion as criteria. It should 
be well emphasized that classification criteria are not equal to 
diagnositic criteria, so some SSc patients do not fall into the 
new ACR/EULAR classification, although compared to the 
previously mentioned ACR and LeRoy-Medsger classifica-
tions, it was found to be superior with a more than 90% sensi-
tivity and specificity in early SSc cases [14]. According to the 
latest consensus, very early SSc can be defined as Raynoud’s 
phenomenon plus positivity of scleroderma-associated an-
tibodies or abnormal nailfold capillaroscopy, all without in-
ternal organ involvement [16]. It should be noted that these 
criteria are not yet validated in children.
Interstitial Lung Disease
Interstitial lung disease (ILD) is present in 70-80% of SSc 
patients, with one fourth of them exhibiting definite pulmo-
nary fibrosis [17], which is much rarer in pediatric patients. 
Lung disease has now become the main cause of mortality in 
systemic sclerosis [18]. Experts agree that tools for ILD ass-
esment and follow-up should be implemented regularly by 
conducting at least 6 to 12 monthly pulmorary function tests 
(PFTs), including high-resolution computed tomography 
(HRCT) [19]. Panigada et al. use PFTs on their own to avoid 
unnecessary HRCTs in pediatric patients [20]. PFTs should 
include forced vital capacity (FVC) measurements and diffu-
sion studies (DLCO). Goh et al. drew attention to the fact that 
in adults, the use of single PFTs or HRCTs in disease extent 
evaluation can be misleading, so to identify disease severity 
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they proposed implementing a staging system by combining 
the two methods. Its aim is to differenciate low and high risk 
patients as a robust difference that could be found in disease 
outcome between the two groups. High risk patients are those 
with an HRCT extent greater than 20% and a FVC less than 
70% [19]. Bouros et al. emphasized that non-specific intersti-
tial pneumonia is the main histological finding in SSC-ILD. 
After matching patient data with histological patterns, they 
concluded that the clinical findings of initial pulmonary func-
tion test results and deterioration rates are superior to histo-
logical findings in forecasting disease severity [21]. Routine 
use of bronchoalveolar lavage (BAL) is not recommended in 
SSc-ILD [22].  For treatment, the most recognized regimen 
is cyclophosphamide pulses followed by mycophenolate-
mofetil (MFF) or azathioprin [23,24], or primary treatment 
with MFF. In non-responders, a rescue rituximab treatment 
option is available [25]. As a last resort, a bilateral lung trans-
plant or autologous bone marrow transplant are options [25-
27]. Patients who underwent pulmonary transplants have 
similar survival rates to those with idiopathic pulmonary fi-
brosis. The only significant difference between the two groups 
was the higher prevalence of acute rejection in SSc patients 
[26]. The incidence of lung cancer was found to be higher in 
adult patients with SSc-ILD [28].
Pulmonary Arterial Hypertension
Pulmonary vasculopathy and chronic SSc lung involv-
ment may lead to pulmonary arterial hypertension (PAH), 
which is present in nearly 10-15% of adult and 7-10% of pedi-
atric scleroderma patients [7,29,30]. PAH has also become 
one of the major causes of SSc-related deaths in the last 30 
years, responsible for approximately 30% of mortalities [18]. 
A French study demonstrated that patients without PAH 
have a lower mortality rate compared to PAH patients (56% 
3-year mortality versus 94%, respectively) [31]. Early diagno-
sis and intervention seemed to delay PAH-associated morbid-
ity and mortality [32,33]. Pulmonary veno-occlusive disease 
(PVOD) is a new field of interest, as patients having this dis-
order appear to exhibit poor survival. PVOD is characterised 
by the radiological triad of lymph node enlargement, centri-
lobular ground-glass opacities and septal lines [34]. The gold 
standard diagnostic tool for PAH is right heart catheterisation 
(RHC). Experts agree on the fact that only selected patients 
should undergo this invasive examination. In juvenile systemic 
sclerosis, the suggested clinical care includes the following: a 
multi-system baseline visit plus follow-up visits scheduled 
every 6 months for PFTs, NTproBNP and cardiac ultrasound 
according to the Juvenile Systemic Sclerosis Inception Cohort 
[35]. For adult patients, there are two major, novel recom-
mendations to perform this selection. Based on the two-step 
DETECT-score, in the first step, any SSc patient should be 
screened for telangiectasias, lung function (FVC and DLCO), 
serum urate, anti-centromere antibody, N-terminal probrain 
natriuretic peptide (NTproBNP) and right axis deviation 
on ECG. By giving weighted points, they recommend that 
high-risk patients be examined with transthoracal echocar-
diography (right atrium area and tricuspid regurgitant veloc-
ity should be assessed). PAH-suspected cases should then be 
evaluated by RHC [36].  Another expert consensus released 
in 2014 suggests that patients with suspicion of severe PAH 
(i.e., having any sign of right heart failure) should be directly 
referred for RHC. They suggested that in order to estimate 
the necessity to perform RHC in patients without right-heart 
failure, patients with clinically significant dyspnoea (progres-
sive dyspnoea over the past 3 months, unexplained dyspnoea 
and worsening of WHO dyspnoea functional class) should 
be sent for transthoracal echocardiography and lung function 
tests (DLCO) [37]. Ambiguous RHC results augurs the likely 
development of PAH [38]. WHO suggests PAH screening in 
all SSc patients [39].  Khanna et al. proposed a baseline visit, 
annual screening panels and reevaluation immediately if new 
symptoms arise. They suggest the use of the DETECT algo-
rithm in patients with low DLCO and long disease duration 
(greater than 3 years)  [40]. Regarding treatment, the endothe-
lin-1 antagonist, bosentan, should be considered in adults as a 
first line of treatment according to 2009 EULAR recommen-
dations. Positive pediatric results were also found with its use 
[41,42]. The selective ETA endothelin receptor antagonist, 
sitexantan, can be used as an alternative if bosentan turns out 
to be ineffective [43]. Oral sildenafil may also be used as an 
option if bosentan cannot be administered [41]. Continuous 
intravenous eporostenol (a prostaglandin analogue) is the 
treatment of choice in severe, therapy-resistant PAH [41]. In 
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severe patients a combination therapy of the above mentioned 
is suggested.
Heart Involvement
Myocardial fibrosis in scleroderma may result in con-
duction defects, arrythmias, sudden cardiac death and also 
congestive heart failure [44,45]. It should be emphasized that 
cardiac involvement (cardiac failure or arrythmias) can be a 
significant cause of death in jSSc, based on data collected from 
international patient databases [7,46]. In adults, because of 
the well-known problem of PAH, the left heart involvement 
was nearly neglected, but may still occur [47]. Regularly per-
formed echocardiography and ECG are the tools for routine 
screening and some centers also include 24-hour Holter mon-
itoring. A heart MRI can also be informative for determining 
the severity of myocardial fibrosis [48]. The use of an implant-
able cardioverter defibrillator (ICD) is recommended for the 
prevention of sudden cardiac death in cases of malignant ar-
rythmias in high-risk patients [44]. 
Renal Crisis
Scleroderma renal crisis (SRC) used to be the major 
cause of mortality before the introduction of ACE-inhibitors 
[18]. They offer greater than four-fold 1-year survival com-
pared to non-treated patients and result in notably decreased 
SRC-related mortality [49]. However, no controlled clinical 
trial has yet been conducted [41]. Individual risk factors for 
developing renal crises include new anaemia, new cardiac 
events, diffuse skin thickening, rapidly progressive skin thick-
ening (a greater than 40 units of skin score increase per year), 
an SSc disease duration of more than 4 years,  anti–RNA poly-
merase III antibody positivity and most importantly steroid 
use [50,51]. In conclusion, SSc, and steroid-recieving patients 
in particular, should be regularly monitored for renal function 
and blood pressure and if needed, treated with ACE-inhibitors 
according to the EULAR consensus [41]. Actual SSc kidney 
disease is a rarity in pediatric patients, including findings of se-
rum anti-RNA polymerase III positivity [6].
Gastrointestinal Involvement
Gastrointestinal (GI) tract involvement is one of the 
most common internal organ manifestations in both sclero-
derma forms, which can be a very early symptom of the dis-
ease [52]. Notably it is seen less frequently in the pediatric 
population [3]. Although esophagus dysfunction is the most 
frequent feature, any part of the GI tract can be affected [53]. 
Scleroderma-related gut complications include problems as-
sociated with bowel dismotility (disphagia, intestinal pseudo-
obstruction, rectal prolapse, obstipation, etc.) and its conse-
quences (e.g., malabsorption and weight loss, small bowel 
bacterial overgrowth syndrome, gastroesophageal reflux 
disease). The underlying pathological findings are fibrosis in 
the bowel wall, leading to muscle atrophy and nerve damage, 
but vasculopathy seems to play an important role as well [54]. 
Gastric antral vascular ectasia (GAVE), also known as “wa-
termelon-stomach,” is a rare form of GI vasculopathy in SSc 
that is associated with the formation of anti-RNA-polymerase 
III antibodies [55,56]. GAVE may cause severe bleeding and 
anaemia, requiring blood transfusions [56]. Radic et al. found 
that H. pylori infection may be associated with SSc severity 
[57]. A higher prevalence of Barret’s esophagus was found in 
SSc, which seems to worsen the risk for developing neoplastic 
disease [58]. Routine diagnostics should include identifying 
specific symptoms in the patient’s history, abdominal ultra-
sound, upper and lower GI endocopy, an H2 breath test and 
even fecal calprotectin [59]. Esophageal dilatation, as seen 
with non-invasive HRCT, can function as a good predictor for 
esophagus dismotility and is superior to scintigraphy [60]. Ac-
cording to EULAR therapeutical recommendations, proton-
pump inhibitors (PPI) should be given for the prevention of 
gastic complications (GERD, ulcers, GAVE). Dismotility-
related symptoms may be relieved by prokinetic drugs (e.g., 
cisapride, mosapride, metoclopramide) [41]. For bacterial 
overgrowth problems treatment with rotated antibiotics may 
be useful [41]. H. pylori eradication seems to be beneficial if 
infection is proven [57]. In the absence of RCTs, these recom-
mendations are based largely on expert opinion, and not on 
strong evidence  [41]. For GAVE, several local endoscopic 
therapy options (argon plasma coagulation, laser photocoagu-
lation, endoscopic band ligation, hot biopsy forceps and mo-
nopolar electrocoagulation so as injection of 5% polidocanol) 
are available, so surgery (gastrectomy, antrectomy) is very sel-
domly needed [55].
For children, we have the same therapeutic options as in 
adults, but until now, no
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Skin Involvement and Digital Vasculopthy
Skin involvement and digital vasculopathy (Raynaud’s 
phenomenon, digital ulcerations) are universal features of scle-
roderma. They are represented in each classification criteria for 
both SSc and jSSc. Although bilateral skin thickening proximal 
to the MCP joints is in and of itself diagnostic for scleroder-
ma, any part of the skin can be effected. Rodnan introduced 
a scoring system to measure disease activity by palpating skin 
thickness in 17 anatomical regions. Its modified version is in 
widespead use for assessment, follow-up and treatment moni-
toring, however, it has a high interobserver variability and has 
not been validated for pediatric use [16,61,62]. In a study with 
”healthy children” the problems and suggestions for adapting 
were suggested [61]. By using a durometer this variability can 
be reduced and its use was comparable to mRSS and was even 
found to be reliable for disease activity monitoring [63, 64]. 
In certain anatomic areas, however, where bony structures are 
found directly beneath the surface, the durometer cannot be 
used and in the adult ’SSc world’, it is still not used on a regular 
basis. 
Raynoud’s phenomenon (RP) associated with abnor-
mal nailfold capillaroscopy and the presence of SSc autoan-
tibodies are hallmarks for early disease as mentioned above. 
Sulli et al. described the typical abnormalities found during 
capillaroscopy in adults, including enlarged capillaries, giant 
capillary loops, microhaemorrhages, loss of capillaries, disor-
ganisation of the capillary array and capillary ramifications. It 
is emphasized that these findings have not yet been adapted 
to children, as several studies indicate that normal patterns are 
different in children, which evolve during maturation [65,66]. 
Therefore, standardized age-specific normal values are weight-
ed to enhance the clinical value of capillaroscopy findings in 
jSSc [62,67,68]. Several new promising techniques have been 
described in the literature, such as ultrasound-based methods, 
laser Doppler, and optical computed tomography [62], but 
have yet to be validated.
Previously published data suggest that baseline skin score 
and the improvement rate was associated with mortality, al-
though Shand et al. assume a more complex relationship be-
tween skin scores and visceral manifestations [69-72]. Agents 
used for ILD treatment (cyclophosphamide, azathioprine, 
MMF) have a reported beneficial effect on skin scores, as well 
as methotrexate. Prevention of RP can be established by using 
nifedipine per os and in severe cases, intravenous iloprost is 
also available [41]. Bosentan had a positive effect on skin ul-
cers and is recommended when other therapies are ineffective 
[41,73].
Measuring Disease Activity
It is critical that all patients are subjected to a full disease 
activity evaluation [74]. The European Scleroderma Study 
Group, representing international efforts, developed a pre-
liminary activity index for adult patients [75-78]. Czirják et al. 
validated the index and according to their results, the validity 
of the EScSG activity index was found to be good, although 
lung-related disease activity may have not been sufficiently 
represented [78].
La Torre et al. released a pediatric disease severity score 
( J4S) in 2012, which is a pediatric adaption of the adult 
Medsger severity score [79,80]. This score, which can be ap-
plied to basic patient assessment, as well as follow-up, incor-
porates all internal organ dysfunctions and skin involvement 
[81]. It mainly reflects the accumulated damage caused by the 
disease and not so much as its activity.
In the framework of the juvenile scleroderma working 
group of the Paediatric Rheumatology European Society 
(PRES JSWG), we started to develop an activity index for jSSc. 
We established a system with proposed items for assessing the 
activity of jSSc and constructed a survey using ©SurveyMon-
key in which all participants of the paediatric rheumatology 
email board, the members of the PRES juvenile scleroderma 
working group and the active participants of the juvenile scle-
roderma inception cohort project were invited to participate. 
The web-based survey is now closed and results will be pub-
lished soon.
Biomarkers
Classic humoral antinuclear antibodies (ANA) are al-
most exclusively (more than 90%) positive in all SSc patients 
according to a recently published paper based on an interna-
tional register of patient data [3]. Anti-topoisomerase-1 (a.k.a 
scl-70) may predict ILD or renal crisis [82]. Anti-RNA-poly-
merase I and III antibodies are associated with renal disease, 
as mentioned above [50]. Anti-centromere antibodies (ACA) 
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may indicate localised disease and PAH [83]. Antinucleolar 
antibodies (fibrillarin, Th/To) may be present as well, predict-
ing severe disease or PAH [84]. Any antinucleolar antibody, 
but primarily anti-PM-SCL and anti-U1RNP, can indicate a 
sign of myositis overlap syndrome [84,85]. These myositis-
related antibodies are significantly more common in child-
hood, such as in overlap syndromes. In contrast, ACA and an-
ti-RNA-polymerase III antibodies were less frequently found 
compared to adult patients [6]. No difference was found 
between the presence of anti-scl-70 antibodies [3]. All these 
markers signify risks for certain organ involvement but do not 
fluctuate according to the level of the activity of the disease. 
The above mentioned pro-BNP is an accepted marker of myo-
cardial stress in PAH monitoring [86], which is supported by 
pediatric studies [87-89]. Several novel biomarkers of the dis-
ease have recently been reported, with most of them relating to 
fibrosis pathogenesis. In a juvenile SSc patient group, Vesely et 
al., examining the role of a pneumocyte-derived glycoprotein 
(KL-6), found normal serum levels in healthy controls and 
non-ILD patients but high levels in ILD patients [90]. TGF-
beta-1 is known for its key role in scleroderma pathogenesis 
[91]. Lee et al. found an association between TGF-beta-1 
and chinitase-1, a substance produced in the lung, which 
they propose to be a new marker appropriate for monitoring 
ILD severity [92]. Celeste et. al. found a correlation between 
serum carbohydrate antigen 15.3 levels  and HRCT disease 
severity in scleroderma [93]. Using a proteomic-wide analy-
sis, van Born’s research group identified a Toll-like receptor 
agonist, S100A8/A9, and plasmacytoid dendritic cell-derived 
CXCL4 as novel ILD biomarkers [94,95].  High serum lysyl 
oxidase levels in SSc patients seem to correlate specifically 
with skin fibrosis [96].
Vitamin D Levels
Vitamin D plays a significant role in the modulation of 
the immune system, exerting effects on innate immune cells, 
antigen presenting cells, macrophages, and T and B lympho-
cytes [97]. Briefly, vitamin D shifts the immune system to-
wards a ’more tolerogenic’ status [98]. Low levels of vitamin D 
are also present in the healthy population; therefore, it is diffi-
cult to evaluate the clinical significance of the high prevalence 
of vitamin D deficiency in patients with autoimmune diseases, 
which has been confirmed by several cross-sectional studies. 
Very low levels of vitamin D (< 10 ng/mL) are associated with 
certain symptoms and correlate with disease activity in SLE 
[99-101]. Several factors can influence the level of vitamin D 
in patients with scleroderma, as skin fibrosis can be altered with 
sun exposure and gut involvement can lead to malabsorption. 
Accordingly, vitamin D deficiency has been documented in 
many cross-sectional studies [102-104]. Some studies dem-
onstrated that low vitamin D levels inversely correlate with 
disease activity [102,104,105]. Based on these observations 
it is assumed that vitamin D supplementation might modify 
disease course, but to this date there is no prospective rand-
omized study available to prove this hypothesis. Since we 
know that patients with scleroderma are at risk for osteoporo-
sis and osteoporosis-related fractures, regular screening of vita-
min D levels (and supplementation of vitamin D if indicated) 
is advocated [106].
Biologics in SSc Treatment
The use of biological therapies is a new, active field in SSc 
research. Regarding most drugs, no extensive RCTs have been 
conducted yet; however, a number of case series are currently 
available. Present biologics have not provided outstanding 
results and are therefore not presently in routine use. Classic 
TNF-alpha blockers seem to improve arthritis in SSc without 
significantly altering mRSS or causing serious adverse events 
[107,108]. In vitro results, however, support the theory that 
they may worsen fibrosis through the promotion of TGF-beta 
secretion [109]. The IL-6 blocker, tocilizumab, also showed 
positive effects on joint disease, myopathy and skin involve-
ment [110,111]. The role of rituximab in ILD is mentioned 
above, but further studies are in progress to determine wheth-
er it has other beneficial effects. B-cell targeted therapies are 
emerging [112-114]. Interferon type 1, which may also play 
a role in SSc pathogenesis, might be targeted later on [115]. 
A number of novel biologics in development are currently 
undergoing clinical trials (long-acting anti-IL-1 therapy, beli-
mumab, abatacept, anti-IL-17, etc.). The literature is also lack-
ing pediatric studies and case reports in this field.
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